NCT05817214View on ClinicalTrials.gov

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2027

Conditions
Cervical Cancer
Interventions
DRUG

Cadonilimab

All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1

DRUG

Anlotinib

All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.

DRUG

Granulocyte-Macrophage Colony-Stimulating Factor

All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.

Trial Locations (1)

430071

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
collaborator

Akeso Biopharma Co., Ltd.

UNKNOWN

lead

Zhongnan Hospital

OTHER